Markos Leggas

Summary

Affiliation: University of Kentucky
Country: USA

Publications

  1. ncbi Validation of an HPLC method for analysis of DB-67 and its water soluble prodrug in mouse plasma
    Jamie Horn
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 844:15-22. 2006
  2. ncbi Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo
    Markos Leggas
    Departments of Pharmaceutical Sciences, Hematology Oncology, and Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer Res 66:4802-7. 2006
  3. ncbi Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice
    Clinton F Stewart
    Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
    Cancer Res 64:7491-9. 2004
  4. ncbi Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution
    Kazumasa Takenaka
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105, USA
    Cancer Res 67:6965-72. 2007
  5. ncbi Mrp4 confers resistance to topotecan and protects the brain from chemotherapy
    Markos Leggas
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105 2794, USA
    Mol Cell Biol 24:7612-21. 2004
  6. ncbi Metabolic pathways of the camptothecin analog AR-67
    Jamie Horn
    Department of Pharmaceutical Science, College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA
    Drug Metab Dispos 39:683-92. 2011
  7. ncbi Microbore HPLC method with online microdialysis for measurement of topotecan lactone and carboxylate in murine CSF
    Markos Leggas
    Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
    J Pharm Sci 93:2284-95. 2004
  8. ncbi Abrogation of microcystin cytotoxicity by MAP kinase inhibitors and N-acetyl cysteine is confounded by OATPIB1 uptake activity inhibition
    Abigail Daily
    Department of Pediatrics, College of Medicine, University of Kentucky, Lexington, KY 40536, USA
    Toxicon 55:827-37. 2010
  9. ncbi Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants: optimization and in vitro characterization
    Xiuling Lu
    Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536 0082, USA
    AAPS J 10:133-40. 2008
  10. ncbi Progesterone acts via progesterone receptors A and B to regulate breast cancer resistance protein expression
    Mary Vore
    Graduate Center for Toxicology, University of Kentucky, 1095 VA Dr, 306 HSRB, Lexington, KY 40536 0305, USA
    Mol Pharmacol 73:613-5. 2008

Research Grants

  1. Phase I and Biological Studies of DB67 - A Blood Stable Camptothecin
    Markos Leggas; Fiscal Year: 2007

Collaborators

Detail Information

Publications18

  1. ncbi Validation of an HPLC method for analysis of DB-67 and its water soluble prodrug in mouse plasma
    Jamie Horn
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 844:15-22. 2006
    ..The assay was found to be suitable for the analysis of DB-67 lactone and carboxylate in pharmacokinetic studies following intravenous administration of DB-67 or its delta-aminobutyric acid ester derivative...
  2. ncbi Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo
    Markos Leggas
    Departments of Pharmaceutical Sciences, Hematology Oncology, and Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer Res 66:4802-7. 2006
    ..4-AQ molecules may offer a means to increase the low and variable oral drug absorption of transporter substrates while decreasing interpatient variability and reversing tumor drug resistance...
  3. ncbi Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice
    Clinton F Stewart
    Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
    Cancer Res 64:7491-9. 2004
    ....
  4. ncbi Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution
    Kazumasa Takenaka
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105, USA
    Cancer Res 67:6965-72. 2007
    ..This new knowledge will facilitate an understanding of how Abcg2 and Mrp4, separately and in combination, protect against purine analogue host toxicity as well as resistance to chemotherapy...
  5. ncbi Mrp4 confers resistance to topotecan and protects the brain from chemotherapy
    Markos Leggas
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105 2794, USA
    Mol Cell Biol 24:7612-21. 2004
    ....
  6. ncbi Metabolic pathways of the camptothecin analog AR-67
    Jamie Horn
    Department of Pharmaceutical Science, College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA
    Drug Metab Dispos 39:683-92. 2011
    ....
  7. ncbi Microbore HPLC method with online microdialysis for measurement of topotecan lactone and carboxylate in murine CSF
    Markos Leggas
    Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
    J Pharm Sci 93:2284-95. 2004
    ..The system allows for the determination of TPT pharmacokinetics in murine CSF and provides a tool to extend pharmacological studies in this brain compartment...
  8. ncbi Abrogation of microcystin cytotoxicity by MAP kinase inhibitors and N-acetyl cysteine is confounded by OATPIB1 uptake activity inhibition
    Abigail Daily
    Department of Pediatrics, College of Medicine, University of Kentucky, Lexington, KY 40536, USA
    Toxicon 55:827-37. 2010
    ..Finally, growth of OATP1B1-expressing HeLa xenografts was inhibited by MCLR, suggesting that MCLR structural analogs selected for a broader therapeutic index could target OATP-expressing tumors...
  9. ncbi Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants: optimization and in vitro characterization
    Xiuling Lu
    Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536 0082, USA
    AAPS J 10:133-40. 2008
    ....
  10. ncbi Progesterone acts via progesterone receptors A and B to regulate breast cancer resistance protein expression
    Mary Vore
    Graduate Center for Toxicology, University of Kentucky, 1095 VA Dr, 306 HSRB, Lexington, KY 40536 0305, USA
    Mol Pharmacol 73:613-5. 2008
    ..This issue of Molecular Pharmacology includes a study (p. 845) now conclusively demonstrating that progesterone acts via the progesterone A and B receptors to regulate BCRP expression in a placental cell line...
  11. ncbi Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors
    Val R Adams
    Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536, USA
    Clin Ther 29:1338-53. 2007
    ....
  12. ncbi Dependence of nelfinavir brain uptake on dose and tissue concentrations of the selective P-glycoprotein inhibitor zosuquidar in rats
    Bradley D Anderson
    University of Kentucky, Department of Pharmaceutical Sciences, ASTeCC Bldg, Room A323A, Lexington, KY 40506 0286, USA
    Drug Metab Dispos 34:653-9. 2006
    ....
  13. ncbi Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts
    Markos Leggas
    Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA
    Clin Cancer Res 8:3000-7. 2002
    ....
  14. ncbi N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) as a chemical ATP-binding cassette transporter family G member 2 (Abcg2) knockout model to study nitrofurantoin transfe
    Lipeng Wang
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 725 Rose Street, Lexington, KY 40536, USA
    Drug Metab Dispos 36:2591-6. 2008
    ..GF120918 is particularly useful as a rat chemical knockout model to establish ABCG2's role in drug transfer into milk during breastfeeding...
  15. ncbi Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice
    Mahfoud Assem
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    J Biol Chem 279:22250-7. 2004
    ....
  16. ncbi Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy
    Markos Leggas
    Department of Pharmaceutical Sciences, The College of Pharmacy, University of Kentucky, Lexington, KY, USA
    Cancer Chemother Pharmacol 63:731-43. 2009
    ..To translate these findings to patients, we have undertaken a Phase 1/2 clinical trial...
  17. ncbi Nanotemplate-engineered nanoparticles containing gadolinium for magnetic resonance imaging of tumors
    Donghua Zhu
    Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536 0082, USA
    Invest Radiol 43:129-40. 2008
    ..To design nanoparticles containing accessible gadolinium atoms (Gd-NPs) as a contrast agent for magnetic resonance imaging of tumors...
  18. ncbi A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies
    Susanne M Arnold
    Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40536 0082, USA
    Clin Cancer Res 16:673-80. 2010
    ..EXPERIMENTAL DESIGN AND METHODS: AR-67 was infused over 1 hour daily five times, every 21 days, using an accelerated titration trial design. Plasma was collected on the 1st and 4th day of cycle 1 to determine pharmacokinetic parameters...

Research Grants2

  1. Phase I and Biological Studies of DB67 - A Blood Stable Camptothecin
    Markos Leggas; Fiscal Year: 2007
    ..Ultimately, the objective is to use DB-67 as a single agent or in combination with other molecular-targeted therapies or cytotoxics in frontline therapy with the goal to improve overall patient outcome. ..